Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer Combines Operations With Wyeth
Pfizer has combined operations with Wyeth following the closing of the acquisition on 15 October, 2009. Pfizer can now offer products in human, animal, and consumer health, including
Pfizer has combined operations with Wyeth following the closing of the acquisition on 15 October, 2009. Pfizer can now offer products in human, animal, and consumer health, including
Access Pharmaceuticals (Access ) has provided an update on it’s European launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment
Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved AstraZeneca’s Symbicort Turbuhaler (budesonide/formoterol) for the maintenance treatment of bronchial asthma in patients aged 16 and over when
Targacept has presented data from its recently completed phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD. Reportedly,
Clinical Center of Serbia, Institute for Cardiovascular Diseases has treated its first patient with a cell-based therapy for heart failure. The patient is participating in an international trial
Pharming Group has reported net loss E23.1m for the third quarter which ended on September 30, 2009. Basic and diluted earnings per share decreased to E0.22 compared to
PIKAMAB has secured exclusive rights to two issued US patents from Hospital for Special Surgery, New York. Reportedly, PIKAMAB is developing Lupus Therasight, a theragnostic product that will
BASF has expanded its application lab for epoxy resin systems at the Ludwigshafen site. Here the company develops new systems and adapts their processing parameters to the specific
Germany-based Merck and Dyesol have signed an agreement to collaborate in the development of electrolytes for use in Dye Solar Cells (DSC). Reportedly, this joint development agreement is
Graffinity Pharmaceuticals (Graffinity) has entered into a drug discovery research collaboration with Genentech, a wholly-owned member of the Roche Group. With this collaboration Genentech is expected to gain